Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
System-State: Number of processed items 23.066 Notifications successully processed since Inception
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
FR0004065605
State: 15.01.2025 | 6AM
Do you already know our new terminal view? Click here.
FIGI: BBG00M0C8GJ0
MEDCL

Medincell S.A.
GICS: - · Sector: - · Sub-Sector: -
NAME
Medincell S.A.
ISIN
FR0004065605
TICKER
MEDCL
MIC
XPAR
REUTERS
MEDCL.PA
BLOOMBERG
MEDCL FP
Thu, 12.12.2024       Medincell

Medincell (Paris:MEDCL) joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy. Medincell joins also the CAC Mid 60 index. Christophe Douat, CEO of Medincell, said: “Just six years after our IPO, Medincell joins the SBF 120, a rec...
Mon, 09.12.2024       Medincell

Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed the following benefits when comparing patients treated with F14/mdc-CWM (n=51) to those in the control group (n=57)1: 70% reduction in the number of opioid users at 3 months post-surg...
Wed, 06.11.2024       Medincell

ACCESS HERE THE COMPLETE PRESS RELEASE Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today as part of its Q3 2024 results, the following information: About UZEDY® Updated 2024 Revenue Outlook: Increased from $80 million to $100 million U.S. Revenues Year-to-Date 2024: $75 million U.S. Revenues for Q3 2024: $35 million M...
Mon, 04.11.2024       Medincell

Medincell (Paris:MEDCL): ACCESS HERE THE COMPLETE PRESS RELEASE TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia. Findings demonstrate significant improvement in soci...
Mon, 23.09.2024       Medincell

Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘749 / mdc-TJK) in adult patients diagnosed with schizophrenia. Richard Malamut, Chief Medical Officer of Medincell, said: “In addition to publishing the positive efficacy results for the primary and seconda...
Mon, 23.09.2024       Medincell

New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified. Perseris manufacturer announced in July 2024 the discontinuation of its commercial...
Thu, 05.09.2024       Medincell

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22nd Annual Global Healthcare Conference held yesterday that c.99% of the targeted injections for submission have been performed as of today (replay available here). Teva also confirmed that the full submission safety results a...
Tue, 03.09.2024       Medincell

Collaboration with AbbVie Initiation of preclinical and supportive CMC* work to advance LAI candidate into clinical development Collaboration with Teva UZEDY® (risperidone LAI) Reaffirming revenue guidance for 2024 by Teva: c.$80 million Exploring an additional indication for the treatment of Bipolar I Disorder in adults Olanza...

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.